Neda Laiteerapong to Cost-Benefit Analysis
This is a "connection" page, showing publications Neda Laiteerapong has written about Cost-Benefit Analysis.
Connection Strength
0.644
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.182
-
Economic Simulation Modeling in Type 2 Diabetes. Curr Diab Rep. 2020 05 17; 20(7):24.
Score: 0.154
-
Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 02 06; 168(3):170-178.
Score: 0.130
-
The public health implications of the cost-effectiveness of bariatric surgery for diabetes. Diabetes Care. 2010 Sep; 33(9):2126-8.
Score: 0.079
-
Health economic analyses of the justice community opioid innovation network (JCOIN). J Subst Abuse Treat. 2021 09; 128:108262.
Score: 0.040
-
Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S. J Diabetes Complications. 2017 Jul; 31(7):1139-1144.
Score: 0.031
-
Patients who self-monitor blood glucose and their unused testing results. Am J Manag Care. 2015 Feb 01; 21(2):e119-29.
Score: 0.027